Italian Study Confirms GLP-1 Drugs Enable Type 2 Diabetes Remission in Real-World Setting
核心洞察
A large Italian study of over 14,000 adults with type 2 diabetes (搜索) found that GLP-1 receptor agonists can induce diabetes remission in 5.8% to 18.3% of patients depending on the definition used.
Patients with shorter diabetes duration, higher BMI, fewer complications, and lower baseline insulin use were most likely to achieve remission after starting GLP-1RA therapy.
The most clinically balanced remission definition (R3) showed 12.2% remission rates with improved cardiovascular and microvascular outcomes, including 35% fewer cardiovascular events.
Real-world evidence from Italy demonstrates that GLP-1 receptor agonists can successfully induce type 2 diabetes (搜索) remission, with remission rates varying from 5.8% to 18.3% depending on clinical definitions used. The multicenter study, published in The Lancet Regional Health - Europe, analyzed data from 14,141 Italian adults with type 2 diabetes who initiated GLP-1RA therapy between January 2010 and January 2022.
Study Design and Patient Population
The GLP-1RA for Simplification in Diabetes (GLIMPLES) study collected retrospective electronic health record data with a mean follow-up duration of four years. The average participant was 60 years old with a 10-year diabetes history, a BMI of 32 kg/m², and a baseline HbA1c of 8.1%. Common baseline treatments included metformin, insulin, and sulfonylureas.
The study evaluated remission using four distinct definitions:
- R1: HbA1c <6.5% for ≥3 months without glucose-lowering medication
- R2: Same as R1 but allowing continued GLP-1RA use
- R3: Same as R1 but without new glucose-lowering medications compared to baseline
- R4: Same as R1 regardless of ongoing pharmacotherapy
Remission Rates and Duration
Remission occurred in 5.8% (R1), 6.2% (R2), 12.2% (R3), and 18.3% (R4) of participants. The time to remission averaged six months across all definitions. However, remission duration varied significantly, lasting longer under R3 (9.3 months) and R4 (10.1 months) compared to R1 (6.5 months) and R2 (6.6 months).
The GLP-1RAs used in the study included dulaglutide (50.5%), liraglutide (24.9%), semaglutide (12.1%), exenatide (11%), and lixisenatide (1.4%). Nearly 25% of participants switched GLP-1RAs during follow-up. Average weight loss varied by medication: semaglutide (3.9 kg), exenatide (3.3 kg), dulaglutide (3.1 kg), liraglutide (3 kg), and lixisenatide (2.8 kg).
Clinical Predictors and Outcomes
Remission was more likely among patients with shorter diabetes duration, higher BMI, fewer complications, and lower baseline insulin/SGLT2 inhibitor (搜索) use. Individuals achieving remission demonstrated modest but significant improvements in body weight (−2 kg), HbA1c (−0.9 to −1.0%), blood pressure (−1 to −2 mmHg), and triglycerides (−15 mg/dL) across remission definitions.
Cardiovascular and Microvascular Benefits
The study revealed important differences in clinical outcomes between remission definitions. Changes in estimated glomerular filtration rate (eGFR) were similar across definitions, but R3 was associated with slower urinary albumin-to-creatinine ratio (UACR) progression (~30% less). New-onset microangiopathy (搜索) was 12−16% lower in participants with R1−R3, suggesting a potential metabolic memory effect.
Most notably, R3 was associated with fewer cardiovascular events (HR 0.65), though remission was not associated with differences in macroangiopathy (搜索). The R3 definition represented the most balanced measure, offering moderate prevalence (12.2%), longer durability (9.3 months), and improved microvascular and cardiovascular outcomes.
Clinical Implications
The researchers noted that "T2D remission is not rare after initiation GLP-1RA, its frequency and duration varying by definition. When achieved, remission is associated with durable metabolic improvements up to 4 years and fewer incident complications."
The study's limitations included its retrospective design, absence of mortality data, lack of event adjudication, potential attrition bias, and medication discontinuation not guided by protocol. These factors may influence observed remission rates and outcomes.
The findings provide real-world evidence supporting T2D remission as a realistic therapeutic goal with GLP-1RA therapy, particularly for patients with shorter disease duration and higher BMI. The R3 definition emerged as the most clinically meaningful measure, balancing achievable remission rates with sustained metabolic benefits and reduced complications.